“B-cell Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the B-cell Lymphoma Market.

The B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the B-cell Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel B-cell Lymphoma treatment therapies with a considerable amount of success over the years. 
• B-cell Lymphoma companies working in the treatment market are Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutica, BeiGene, Autolus Limited, SystImmune Inc., Hanmi Pharmaceutical, Xynomic Pharma, Pfizer, ZAI Lab, Oncternal Therapeutics, and others, are developing therapies for the B-cell Lymphoma treatment 

• Emerging B-cell Lymphoma therapies in the different phases of clinical trials are- VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, and others are expected to have a significant impact on the B-cell Lymphoma market in the coming years.   
• In May 2023, Positive topline results from the two studies TRANSCEND FL and TRANSCEND NHL 001, which both evaluated Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including mantle cell lymphoma (MCL), were released by Bristol Myers Squibb. Results demonstrated that both studies accomplished the main objective of the overall response rate, with Breyanzi showing statistically significant and clinically significant responses in FL and MCL that had relapsed or had become resistant to treatment
• In May 2023, To develop, produce, and market next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies, Cellular Biomedicine Group Inc. (CBMG) and Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, have announced a global collaboration and licence agreement
• In May 2023, According to Genmab A/S, the FDA has approved EPKINLYTM (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL resulting from indolent lymphoma, and high-grade B cell lymphoma, following two or more lines of systemic therapy
• In March 2023, A Phase 3 Randomized,Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma was started by Oncternal Therapeutics, Inc
• In January 2023, A proposal from Janssen Biotech, Inc. (“Janssen”) to extend the parties’ collaboration and option agreement on revised terms and conditions was rejected by Fate Therapeutics, Inc., which led to the termination of the agreement and the winding down of all collaboration activities in the first quarter of 2023.

B-cell Lymphoma Overview

B-cell B cells, a subset of immune system cells, are where lymphoma arises. B-cell lymphomas can either be aggressive (fast-growing) or indolent (slow-growing). Non-Hodgkin lymphomas represent the majority of B-cell lymphomas. Non-Hodgkin B-cell lymphomas come in a variety of forms.

Get a Free Sample PDF Report to know more about B-cell Lymphoma Pipeline Therapeutic Assessment-

delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight

Emerging B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

• VIP 924: Vincerx Pharma
• UBX-303-1: Ubix Therapeutics
• BMF-219: Biomea Fusion Inc.
• SHR-A1912: Shanghai Hengrui Pharmaceutica
• Ociperlimab: BeiGene
• AUTO3: Autolus Limited
• GNC-038: SystImmune Inc.
• Poseltinib: Hanmi Pharmaceutical
• Abexinostat: Xynomic Pharmaceuticals
• PF-07901801: Pfizer
• Odronextamab: ZAI Lab
• Zilovertamab: Oncternal Therapeutics 

B-cell Lymphoma Pipeline Therapeutics Assessment

• B-cell Lymphoma Assessment by Product Type
• B-cell Lymphoma By Stage and Product Type
• B-cell Lymphoma Assessment by Route of Administration
• B-cell Lymphoma By Stage and Route of Administration
• B-cell Lymphoma Assessment by Molecule Type
• B-cell Lymphoma by Stage and Molecule Type

DelveInsight’s B-cell Lymphoma Report covers around products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further B-cell Lymphoma product details are provided in the report. Download the B-cell Lymphoma pipeline report to learn more about the emerging B-cell Lymphoma therapies

Some of the key companies in the B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for B-cell Lymphoma are – Oncternal Therapeutics, Inc, ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc, Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation,  Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co., and others.

B-cell Lymphoma Pipeline Analysis:

The B-cell Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of B-cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-cell Lymphoma Treatment.
• B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the B-cell Lymphoma market.
• The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about B-cell Lymphoma drugs and therapies

B-cell Lymphoma Pipeline Market Drivers

• Increase in prevalence of B-cell Lymphoma, launch of several novel therapies for treating B cell Lymphoma are some of the important factors that are fueling the B-cell Lymphoma Market.

B-cell Lymphoma Pipeline Market Barriers 

• However, high cost of the treatment, side effects associated with the therapies and other factors are creating obstacles in the B-cell Lymphoma Market growth.

Scope of B-cell Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key B-cell Lymphoma Companies: Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutica, BeiGene, Autolus Limited, SystImmune Inc., Hanmi Pharmaceutical, Xynomic Pharma, Pfizer, ZAI Lab, Oncternal Therapeutics, and others
• Key B-cell Lymphoma Therapies: VIP 924, UBX-303-1, BMF-219, SHR-A1912, Ociperlimab, AUTO3, GNC-038, Poseltinib, Abexinostat, PF-07901801, Odronextamab, Zilovertamab, and others
• B-cell Lymphoma Therapeutic Assessment: B-cell Lymphoma current marketed and B-cell Lymphoma emerging therapies
• B-cell Lymphoma Market Dynamics: B-cell Lymphoma market drivers and B-cell Lymphoma market barriers 

Request for Sample PDF Report for B-cell Lymphoma Pipeline Assessment and clinical trials

Table of Contents 

1. B-cell Lymphoma Report Introduction

2. B-cell Lymphoma Executive Summary

3. B-cell Lymphoma Overview

4. B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. B-cell Lymphoma Pipeline Therapeutics

6. B-cell Lymphoma Late Stage Products (Phase II/III)

7. B-cell Lymphoma Mid Stage Products (Phase II)

8. B-cell Lymphoma Early Stage Products (Phase I)

9. B-cell Lymphoma Preclinical Stage Products

10. B-cell Lymphoma Therapeutics Assessment

11. B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. B-cell Lymphoma Key Companies

14. B-cell Lymphoma Key Products

15. B-cell Lymphoma Unmet Needs

16 . B-cell Lymphoma Market Drivers and Barriers

17. B-cell Lymphoma Future Perspectives and Conclusion

18. B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services